
sep pm et
summari compani manufactur scientif industri analyt equip liquid
chromatographi thermal analysi mass spectrometri product
nm price-to-earnings oper ep
liquid chromatographi mass spectrometri
market off-set highli competit marketplac
relianc custom demand expens instrument
oct ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
sep stock trade
see sale grow
gener drug well rise global
regulatori standard india new good
servic tax caus purchas delay
late see
purchas order normal begin
expect industri market
continu improv follow
rise soft also look
improv government/academ market
geographi although account
small percentag sale expect
oper margin grow basi point
march congress approv
increas nih budget largest
increas year follow rise
despit presid trump budget
propos call nih budget cut
also see benefit
centuri cure act add
nih budget year note
nih-fund lab account
sale overal govern market
account sale
stock buy-back program addit
remain prior program
view share current trade
forward ep estim
peer averag attract
demand particularli drug industri
improv industri demand drive
fund stabil improv
europ asia also encourag
pharmaceut end-market
broaden concentr larg
global pharma expect demand china
soft sinc due
govern fund delay improv
follow solid growth
risk recommend target price
soften pharmaceut industri
end-market slowdown govern
target price base
slightli peer forward
ep estim market
share leadership howev note
quarterli result volatil instrument
sale account sale yet new
product introduct well receiv
consum sale remain robust
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview corp manufactur distribut servic analyt instrument
pharmaceut life scienc biochem industri academ govern end-market analyt
instrument compon manufactur includ high-perform liquid chromatographi hplc
instrument ultra perform liquid chromatographi uplc column consum mass
spectrometri ms instrument integr analyt instrument thermal
analysi ta rheolog instrument liquid chromatographi standard techniqu identifi
analyz constitu compon variou chemic materi uniqu perform capabl
let separ identifi known chemic materi hplc uplc use analyz
substanc varieti industri qualiti control process engin applic
life scienc industri use hplc uplc primarili identifi new drug
uplc provid comprehens chemic separ faster analysi time compar hplc
ms analyt techniqu use identifi unknown compound quantifi known materi
elucid structur chemic properti molecul measur mass individu
molecul convert ion product serv divers market includ
pharmaceut environment industri
divis make servic thermal analysi rheolog instrument use
physic character polym relat materi thermal analysi measur physic
characterist materi function temperatur chang temperatur affect sever
characterist materi physic state weight dimens mechan electr
properti may measur use thermal analysi techniqu result thermal analysi
wide use develop produc character materi industri plastic chemic
compani introduc acquiti uplc m-class instrument system system deliv
sensit quantifi identifi vanishingli small concentr key molecul particularli
use mass spectrometr detect innov incorpor acquiti uplc m-class
system led intern low-volum design newli redesign fluidic minim dispers
adsorpt loss chromatograph separ compani introduc acquiti
arc system enabl arc multi-flow path technolog bridg gap hplc
uplc emul variou hplc system without alter method gradient tabl enabl
improv chromatograph perform method
market profil market three analyt instrument compet estim
billion billion compani world largest maker chromatographi instrument
chromatographi column relat consum largest market share europ
non-japan asia lead posit japan hplc largest product segment analyt
instrument market uplc instrument gain market share also believ maintain
lead market share mass spectrometri marketplac accord trade public instrument
busi outlook third largest market share estim
competit landscap analyt instrument system market highli competit
compani believ compet primarili basi perform reliabl servic
lesser extent price within hplc uplc ms market competitor includ publicli trade
compani shimadzu corpor
corpor howev believ compani offer compar product acquiti uplc
within thermal analysi market compani princip competitor includ
mettler-toledo intern shimadzu corpor malvern instrument
financi trend sale grown billion billion repres
three-year compound annual growth rate compound-annual-growth-rate adjust ep rose
repres three-year compound-annual-growth-rate repurchas billion common stock
april board author repurchas billion stock
compani anticip use billion repatri cash reduc debt repurchas common stock
senior vice presid
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu
bullish sinc septemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
posit fundament outlook
life scienc tool servic sub-industri
next month think among
fastest-grow sub-industri within
health care sector see solid fund
privat public sourc help drive
billion increas nation
institut nih fy budget
billion septemb
billion increas fy budget
increas contrast presid
trump call cut nih budget
billion billion fy fy
signific fund academ lab
turn account sale life
scienc tool compani averag
trump propos indic
administr prioriti actual fund
determin congress think
signific bipartisan support nih
believ congress disregard trump propos
cut nih budget nonetheless trump
propos budget creat uncertainti
may result project termin
cloud futur research project
view nih budget rose
billion billion
largest percentag increas sinc
includ billion stimulu fund
american recoveri reinvest act
arra
decemb presid obama sign
centuri cure act law law
provid billion year
nation institut split
go cancer moonshot billion
fund precis medicin initi
billion fund brain
initi support alzheim diseas
overal see mid-singl high-singl digit
sale growth emerg market
china remain robust growth region
grow rate mid-teen help fuel
overal industri growth believ demand
strong begin moder
think research lab suffici
equip current need mani
equip compani also diversifi
product line increas sale
consum typic immun
budget constraint expand
area environment food
safeti agricultur growth
end-market expect robust
pharmaceut research
end-market howev note mani life
scienc compani activ pursu
initi commerci non-academ
govern revenu base
compani provid servic
pharmaceut biotech firm
contract research organ see
solid growth next month
view believ pharmaceut biotech
firm increasingli outsourc servic
think increas effici lower
cost also see increas strateg
 life scienc tool
servic rose vs rise
 composit index year date
juli life scienc tool
servic rose vs rise
base index
five-year market price perform sep
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra rais opinion share corpor buy
hold rais target
in-lin peer next ep estim ep
vs estim rais ep estim
sale rose continu strong demand
pharmaceut end-market improv industri market also
encourag end-market demand particularli
industri market soft howev govern
end-market although small fell anticip improv
analyst research note compani news
et cfra keep buy opinion share corpor
keep target slightli peer
forward ep estim see continu sale
momentum ep vs estim keep
ep estim rais ep estim sale
fx benefit rose repres sequenti improv
sale softer expect particularli india mass
spectrometri line sale mass spectrometri improv driven solid
growth core tandem quadrupol product note
high-resolut mass spectrometri line continu affect soft
biomed research sale india flat anticip improv
expect purchas pattern normal advers
impact chang countri good servic tax sale china
grew mid-teen thermal analysi unit grew aid new
et cfra keep buy opinion share corpor
keep target slightli peer
ep estim lead market share
ep vs ahead view sale aid
fx benefit rose strong sale pharmaceut govern end
market respect sale ta product line rose
constant currenc basi instrument sale fell recur sale
rose sale india mass spectrometri product line weaker
expect due soft biomed research believ
temporari along chang within sale team complet
expect sale improv mass spectrometri throughout year sale
india advers impact chang good servic tax gst
expect normal board approv new stock
buy-back program addit remain prior buy-back
corpor rais target
slightli peer ep estim set
ep vs ahead estim sale aid
fx benefit rose broad-bas growth across product
geographi sale pharmaceut end-market rose aid
double-digit growth china rebound india industri
market rose sale govern market rose though note
market volatil guid sale growth mid-singl digit
ep /jeffrey loo cfa
et cfra keep buy opinion share corpor
rais target in-lin
peer forward ep estim rais
ep estim ep
vs ahead estim sale fx benefit rose
broad-bas growth across end-market pharma sale rose
industri government/academ rose see continu
benefit rise global regulatori standard along increas use mass
spectrometri routin workflow process includ food safeti /jeffrey loo
et cfra keep buy opinion share corpor
rais target in-lin
peer forward ep estim ep vs
ahead estim lift estim
sale rose pharmaceut
end-market moder growth high singl digit industri
solid growth govern improv growth prior
geograph sale asia rose europ sale america
fell sale see improv /jeffrey loo
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
